Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1972
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 2
1973 1
1978 4
1979 1
1981 1
1985 1
1988 4
1989 4
1990 4
1991 7
1992 1
1993 3
1994 5
1995 8
1996 5
1997 1
1998 6
1999 6
2000 4
2001 7
2002 2
2003 4
2004 5
2005 3
2006 7
2007 5
2008 5
2009 6
2010 5
2011 3
2012 5
2013 12
2014 9
2015 10
2016 17
2017 14
2018 8
2019 12
2020 17
2021 12
2022 17
2023 12
2024 14
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

257 results

Results by year

Filters applied: . Clear all
Page 1
Hypertrophic Cardiomyopathy: An Overview of Genetics and Management.
Teekakirikul P, Zhu W, Huang HC, Fung E. Teekakirikul P, et al. Biomolecules. 2019 Dec 16;9(12):878. doi: 10.3390/biom9120878. Biomolecules. 2019. PMID: 31888115 Free PMC article. Review.
Hypertrophic cardiomyopathy (HCM) is a genetically heterogeneous cardiac muscle disorder with a diverse natural history, characterized by unexplained left ventricular hypertrophy (LVH), with histopathological hallmarks including myocyte enlargement, myocyte disarray
Hypertrophic cardiomyopathy (HCM) is a genetically heterogeneous cardiac muscle disorder with a diverse natural history, chara
Efficacy and Safety of Mavacamten in the Treatment of Hypertrophic Cardiomyopathy: A Systematic Review.
Bishev D, Fabara S, Loseke I, Alok A, Al-Ani H, Bazikian Y. Bishev D, et al. Heart Lung Circ. 2023 Sep;32(9):1049-1056. doi: 10.1016/j.hlc.2023.05.019. Epub 2023 Jul 14. Heart Lung Circ. 2023. PMID: 37453852 Free article. Review.
BACKGROUND: Current pharmacological options for hypertrophic cardiomyopathy (HCM) are not disease-specific; while it treats symptoms, mavacamten targets the underlying pathology. ...
BACKGROUND: Current pharmacological options for hypertrophic cardiomyopathy (HCM) are not disease-specific; while it treats sy …
Applications of Gene Therapy in Cardiomyopathies.
Argiro A, Bui Q, Hong KN, Ammirati E, Olivotto I, Adler E. Argiro A, et al. JACC Heart Fail. 2024 Feb;12(2):248-260. doi: 10.1016/j.jchf.2023.09.015. Epub 2023 Oct 7. JACC Heart Fail. 2024. PMID: 37966402 Review.
The genetic material is usually delivered though cardiotropic vectors such as adeno-associated virus 9 or engineered capsids. The enthusiasm for gene therapy has been hampered somewhat by adverse events observed in clinical trials, including dose-dependent immunologic reac …
The genetic material is usually delivered though cardiotropic vectors such as adeno-associated virus 9 or engineered capsids. The ent …
Apical Hypertrophic Cardiomyopathy: The Variant Less Known.
Hughes RK, Knott KD, Malcolmson J, Augusto JB, Mohiddin SA, Kellman P, Moon JC, Captur G. Hughes RK, et al. J Am Heart Assoc. 2020 Mar 3;9(5):e015294. doi: 10.1161/JAHA.119.015294. Epub 2020 Feb 28. J Am Heart Assoc. 2020. PMID: 32106746 Free PMC article. Review. No abstract available.
ERK: A Key Player in the Pathophysiology of Cardiac Hypertrophy.
Gallo S, Vitacolonna A, Bonzano A, Comoglio P, Crepaldi T. Gallo S, et al. Int J Mol Sci. 2019 May 1;20(9):2164. doi: 10.3390/ijms20092164. Int J Mol Sci. 2019. PMID: 31052420 Free PMC article. Review.
Specific ERK-associated scaffold proteins are implicated in either cardioprotective or detrimental hypertrophic functions. Interestingly, ERK phosphorylated at threonine 188 and activated ERK5 (the big MAPK 1) are associated with pathological forms of hypertrophy. Finally, …
Specific ERK-associated scaffold proteins are implicated in either cardioprotective or detrimental hypertrophic functions. Interestin …
Mavacamten, a precision medicine for hypertrophic cardiomyopathy: From a motor protein to patients.
Nag S, Gollapudi SK, Del Rio CL, Spudich JA, McDowell R. Nag S, et al. Sci Adv. 2023 Jul 28;9(30):eabo7622. doi: 10.1126/sciadv.abo7622. Epub 2023 Jul 28. Sci Adv. 2023. PMID: 37506209 Free article. Review.
Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder characterized by left ventricular hypertrophy, hyperdynamic contraction, and impaired relaxation of the heart. ...
Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder characterized by left ventricular hypertrophy, hyperdynamic
Dilated cardiomyopathy: the complexity of a diverse genetic architecture.
Hershberger RE, Hedges DJ, Morales A. Hershberger RE, et al. Nat Rev Cardiol. 2013 Sep;10(9):531-47. doi: 10.1038/nrcardio.2013.105. Epub 2013 Jul 30. Nat Rev Cardiol. 2013. PMID: 23900355 Review.
Remarkable progress has been made in understanding the genetic basis of dilated cardiomyopathy (DCM). Rare variants in >30 genes, some also involved in other cardiomyopathies, muscular dystrophy, or syndromic disease, perturb a diverse set of important myocardial protei …
Remarkable progress has been made in understanding the genetic basis of dilated cardiomyopathy (DCM). Rare variants in >30 genes, …
The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms.
Andrade J, Khairy P, Dobrev D, Nattel S. Andrade J, et al. Circ Res. 2014 Apr 25;114(9):1453-68. doi: 10.1161/CIRCRESAHA.114.303211. Circ Res. 2014. PMID: 24763464 Review.
Emerging risk factors include prehypertension, increased pulse pressure, obstructive sleep apnea, high-level physical training, diastolic dysfunction, predisposing gene variants, hypertrophic cardiomyopathy, and congenital heart disease. Potential risk factors are c …
Emerging risk factors include prehypertension, increased pulse pressure, obstructive sleep apnea, high-level physical training, diastolic dy …
Causes of sudden cardiac death in young athletes and non-athletes: systematic review and meta-analysis: Sudden cardiac death in the young.
D'Ascenzi F, Valentini F, Pistoresi S, Frascaro F, Piu P, Cavigli L, Valente S, Focardi M, Cameli M, Bonifazi M, Metra M, Mondillo S. D'Ascenzi F, et al. Trends Cardiovasc Med. 2022 Jul;32(5):299-308. doi: 10.1016/j.tcm.2021.06.001. Epub 2021 Jun 22. Trends Cardiovasc Med. 2022. PMID: 34166791 Review.
Comparing the causes of SCD between athletes and non-athletes, non-ischemic left ventricular scar (NILVS) (5.1% vs. 1.1%, p=0.01) was more frequent in the former, while coronary artery disease (CAD) (19.6% vs. 9.1%, p=0.009), arrhythmogenic cardiomyopathy (ACM) (11. …
Comparing the causes of SCD between athletes and non-athletes, non-ischemic left ventricular scar (NILVS) (5.1% vs. 1.1%, p=0.01) was more f …
MUSCLEMOTION: A Versatile Open Software Tool to Quantify Cardiomyocyte and Cardiac Muscle Contraction In Vitro and In Vivo.
Sala L, van Meer BJ, Tertoolen LGJ, Bakkers J, Bellin M, Davis RP, Denning C, Dieben MAE, Eschenhagen T, Giacomelli E, Grandela C, Hansen A, Holman ER, Jongbloed MRM, Kamel SM, Koopman CD, Lachaud Q, Mannhardt I, Mol MPH, Mosqueira D, Orlova VV, Passier R, Ribeiro MC, Saleem U, Smith GL, Burton FL, Mummery CL. Sala L, et al. Circ Res. 2018 Feb 2;122(3):e5-e16. doi: 10.1161/CIRCRESAHA.117.312067. Epub 2017 Dec 27. Circ Res. 2018. PMID: 29282212 Free PMC article. Review.
257 results